Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 78 Lung Neoplasms 44 Carcinoma, Hepatocellular 42 Small Cell Lung Carcinoma 28 Breast Neoplasms 18 Cholangiocarcinoma 17 Urinary Bladder Neoplasms 16 Biliary Tract Neoplasms 15 Liver Neoplasms 13 Neoplasms 12 Neoplasm Metastasis 12 Triple Negative Breast Neoplasms 11 Pancreatic Neoplasms 11 Ovarian Neoplasms 9 Carcinoma 9 Squamous Cell Carcinoma of Head and Neck 8 Endometrial Neoplasms 7 Colorectal Neoplasms 7 Stomach Neoplasms 6 Carcinoma, Transitional Cell 6 Melanoma 5 Gallbladder Neoplasms 5 Esophageal Neoplasms 5 Carcinoma, Renal Cell 5 Adenocarcinoma Of Esophagus 5 Adenocarcinoma 5 Prostatic Neoplasms 4 Non-Muscle Invasive Bladder Neoplasms 4 Neoplasms by Site 4 Mesothelioma 4

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Hepatobiliary Cancers × durvalumab × 1 year × Clear all

NCT06252753 2025-12-26

LIVER-R

AstraZeneca

Gastrointestinal

Hepatobiliary Cancers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡